Form 4: Third Rock Ventures Sells TNGX Shares

Third Rock Ventures, a 10% owner and director of Tango Therapeutics, sold 302,194 shares of common stock for approximately $2.1 million.

Summary

• Third Rock Ventures IV, L.P., a 10% owner and director of Tango Therapeutics, Inc. (TNGX), disposed of 302,194 shares of common stock.
• The transaction occurred on August 22, 2025, at a weighted average price of $7.00 per share, with individual sales ranging from $7.00 to $7.05.
• The total value of the shares sold is approximately $2,115,358.
• Following this transaction, Third Rock Ventures IV, L.P. directly holds 15,456,881 shares of Tango Therapeutics common stock.
• The sale was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 4

Explanation: The sale by a significant institutional investor and director, while potentially part of a pre-planned strategy, generally carries a slightly negative sentiment as it reduces insider ownership and could be interpreted as a lack of strong future conviction. The 10b5-1 plan mitigates some of the immediate negative implications, but it is still a divestment.

Negatives

• A significant sale by a 10% owner and director could be interpreted by the market as a reduction in confidence in the company's future prospects.
• The transaction represents a decrease in institutional ownership of Tango Therapeutics common stock.

Risks

• Investor sentiment may be negatively impacted by a large insider sale, potentially leading to downward pressure on the stock price.
• Reduced ownership by a significant institutional investor could decrease perceived oversight or strategic support for the company.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Tango Therapeutics' future performance or strategic direction.

Management Comments

• The filing does not contain direct quotes or paraphrased statements from company management, but notes that the sale was executed by Kevin Gillis, Chief Operating Officer of TRV GP IV, LLC, acting as general partner for the reporting entities.

Industry Context

Insider sales, particularly by significant institutional investors like venture capital firms, are common as companies mature or as funds reach the end of their investment horizon. While this sale is by a 10% owner and director, the execution under a Rule 10b5-1 plan suggests a pre-determined liquidation strategy rather than an immediate reaction to new information. In the biotechnology sector, venture capital firms often divest holdings as portfolio companies achieve certain milestones or as part of routine fund management.

Related Party Transactions

• The filing details the beneficial ownership structure where Third Rock Ventures GP IV, L.P. is the general partner of Third Rock Ventures IV, L.P., and TRV GP IV, LLC is the general partner of Third Rock Ventures GP IV, L.P. Each disclaims beneficial ownership except to the extent of pecuniary interest.

Stakeholder Impact

• Shareholders: May perceive the sale by a significant institutional investor and director as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
• Company: Could face questions regarding the implications of a major investor reducing its stake, potentially impacting future capital raising efforts or strategic partnerships.

Key Dates

Recommendation

While the sale by a 10% owner and director is a notable event, it was executed under a Rule 10b5-1 plan, suggesting a pre-determined divestment strategy rather than an immediate reaction to new negative information. Without additional context on Tango Therapeutics' operational performance or other market factors, a 'hold' recommendation is appropriate. Investors should monitor future insider activity and company developments, but this single transaction, while significant, does not immediately warrant a 'sell' given the pre-planned nature.

Keywords

Tango Therapeutics, TNGX, Third Rock Ventures, Insider Sale, Form 4, Stock Transaction, Biotechnology, Venture Capital, 10b5-1 Plan